ES2363358B1 - Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. - Google Patents

Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. Download PDF

Info

Publication number
ES2363358B1
ES2363358B1 ES200900928A ES200900928A ES2363358B1 ES 2363358 B1 ES2363358 B1 ES 2363358B1 ES 200900928 A ES200900928 A ES 200900928A ES 200900928 A ES200900928 A ES 200900928A ES 2363358 B1 ES2363358 B1 ES 2363358B1
Authority
ES
Spain
Prior art keywords
lif
cytokine
type
cell proliferation
type cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES200900928A
Other languages
English (en)
Spanish (es)
Other versions
ES2363358A1 (es
Inventor
Joan Seoane Suarez
Silvia Peñuelas Prieto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200900928A priority Critical patent/ES2363358B1/es
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Priority to KR1020207017470A priority patent/KR102373754B1/ko
Priority to US13/138,804 priority patent/US10100112B2/en
Priority to CN201711070081.2A priority patent/CN107964043A/zh
Priority to HUE16155009A priority patent/HUE054196T2/hu
Priority to EA201101450A priority patent/EA201101450A1/ru
Priority to EP10713619A priority patent/EP2414394A2/en
Priority to ES16155009T priority patent/ES2864639T3/es
Priority to SG10202010568RA priority patent/SG10202010568RA/en
Priority to AU2010233791A priority patent/AU2010233791B2/en
Priority to PT161550090T priority patent/PT3045474T/pt
Priority to SM20210153T priority patent/SMT202100153T1/it
Priority to EP16155009.0A priority patent/EP3045474B1/en
Priority to PL16155009T priority patent/PL3045474T3/pl
Priority to KR1020187018827A priority patent/KR20180079470A/ko
Priority to MX2011010425A priority patent/MX336903B/es
Priority to SG2011071834A priority patent/SG175032A1/en
Priority to DK16155009.0T priority patent/DK3045474T3/da
Priority to LTEP16155009.0T priority patent/LT3045474T/lt
Priority to BRPI1015369-1A priority patent/BRPI1015369A2/pt
Priority to JP2012502710A priority patent/JP6207836B2/ja
Priority to KR1020227007752A priority patent/KR20220035978A/ko
Priority to KR1020117026088A priority patent/KR20120100703A/ko
Priority to PCT/EP2010/054499 priority patent/WO2010115868A2/en
Priority to CA2757680A priority patent/CA2757680C/en
Priority to KR1020197022597A priority patent/KR20190093691A/ko
Priority to CN2010800246730A priority patent/CN102574918A/zh
Priority to SI201032059T priority patent/SI3045474T1/sl
Priority to KR1020177030504A priority patent/KR20170121319A/ko
Publication of ES2363358A1 publication Critical patent/ES2363358A1/es
Priority to IL215467A priority patent/IL215467A/en
Priority to ZA2011/07215A priority patent/ZA201107215B/en
Application granted granted Critical
Publication of ES2363358B1 publication Critical patent/ES2363358B1/es
Priority to JP2015178986A priority patent/JP2016040255A/ja
Priority to JP2018152551A priority patent/JP2019006784A/ja
Priority to US16/115,191 priority patent/US20190211095A1/en
Priority to JP2020016672A priority patent/JP2020090522A/ja
Priority to US17/001,530 priority patent/US11999782B2/en
Priority to HRP20210352TT priority patent/HRP20210352T1/hr
Priority to CY20211100232T priority patent/CY1124148T1/el
Priority to JP2021186785A priority patent/JP7197665B2/ja
Priority to US18/652,603 priority patent/US20240400667A1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
ES200900928A 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. Withdrawn - After Issue ES2363358B1 (es)

Priority Applications (40)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US13/138,804 US10100112B2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
CN201711070081.2A CN107964043A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂
HUE16155009A HUE054196T2 (hu) 2009-04-03 2010-04-06 Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
EA201101450A EA201101450A1 (ru) 2009-04-03 2010-04-06 Терапевтические агенты для лечения заболеваний, связанных с нежелательной клеточной пролиферацией
EP10713619A EP2414394A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
ES16155009T ES2864639T3 (es) 2009-04-03 2010-04-06 Agentes terapéuticos para el tratamiento de enfermedades asociadas con proliferación celular no deseada
SG10202010568RA SG10202010568RA (en) 2009-04-03 2010-04-06 Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation
AU2010233791A AU2010233791B2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PT161550090T PT3045474T (pt) 2009-04-03 2010-04-06 Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada
SM20210153T SMT202100153T1 (it) 2009-04-03 2010-04-06 Agenti terapeutici per il trattamento di malattie associate a proliferazione cellulare indesiderata
EP16155009.0A EP3045474B1 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PL16155009T PL3045474T3 (pl) 2009-04-03 2010-04-06 Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórek
KR1020187018827A KR20180079470A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
MX2011010425A MX336903B (es) 2009-04-03 2010-04-06 Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada.
SG2011071834A SG175032A1 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
DK16155009.0T DK3045474T3 (da) 2009-04-03 2010-04-06 Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation
LTEP16155009.0T LT3045474T (lt) 2009-04-03 2010-04-06 Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija
BRPI1015369-1A BRPI1015369A2 (pt) 2009-04-03 2010-04-06 agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada
JP2012502710A JP6207836B2 (ja) 2009-04-03 2010-04-06 望ましくない細胞増殖と関連する疾患の治療のための治療剤
KR1020207017470A KR102373754B1 (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
KR1020227007752A KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
CA2757680A CA2757680C (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
KR1020197022597A KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
CN2010800246730A CN102574918A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂
SI201032059T SI3045474T1 (sl) 2009-04-03 2010-04-06 Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic
KR1020177030504A KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020117026088A KR20120100703A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
IL215467A IL215467A (en) 2009-04-03 2011-10-02 Therapeutic Causes for the Treatment of Diseases Associated with Undesirable Rapid Culture of Cells
ZA2011/07215A ZA201107215B (en) 2009-04-03 2011-10-03 Therapeutic agents for the treatment of diseases associated with undersired cell proliferation
JP2015178986A JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2018152551A JP2019006784A (ja) 2009-04-03 2018-08-14 望ましくない細胞増殖と関連する疾患の治療のための治療剤
US16/115,191 US20190211095A1 (en) 2009-04-03 2018-08-28 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
JP2020016672A JP2020090522A (ja) 2009-04-03 2020-02-04 望ましくない細胞増殖と関連する疾患の治療のための治療剤
US17/001,530 US11999782B2 (en) 2009-04-03 2020-08-24 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HRP20210352TT HRP20210352T1 (hr) 2009-04-03 2021-03-02 Terapeutska sredstva za liječenje bolesti povezanih s neželjenom proliferacijom stanica
CY20211100232T CY1124148T1 (el) 2009-04-03 2021-03-18 Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
JP2021186785A JP7197665B2 (ja) 2009-04-03 2021-11-17 望ましくない細胞増殖と関連する疾患の治療のための治療剤
US18/652,603 US20240400667A1 (en) 2009-04-03 2024-05-01 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.

Publications (2)

Publication Number Publication Date
ES2363358A1 ES2363358A1 (es) 2011-08-01
ES2363358B1 true ES2363358B1 (es) 2012-06-21

Family

ID=42342718

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200900928A Withdrawn - After Issue ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ES16155009T Active ES2864639T3 (es) 2009-04-03 2010-04-06 Agentes terapéuticos para el tratamiento de enfermedades asociadas con proliferación celular no deseada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16155009T Active ES2864639T3 (es) 2009-04-03 2010-04-06 Agentes terapéuticos para el tratamiento de enfermedades asociadas con proliferación celular no deseada

Country Status (24)

Country Link
US (4) US10100112B2 (enExample)
EP (2) EP3045474B1 (enExample)
JP (5) JP6207836B2 (enExample)
KR (6) KR102373754B1 (enExample)
CN (2) CN107964043A (enExample)
AU (1) AU2010233791B2 (enExample)
BR (1) BRPI1015369A2 (enExample)
CA (1) CA2757680C (enExample)
CY (1) CY1124148T1 (enExample)
DK (1) DK3045474T3 (enExample)
EA (1) EA201101450A1 (enExample)
ES (2) ES2363358B1 (enExample)
HR (1) HRP20210352T1 (enExample)
HU (1) HUE054196T2 (enExample)
IL (1) IL215467A (enExample)
LT (1) LT3045474T (enExample)
MX (1) MX336903B (enExample)
PL (1) PL3045474T3 (enExample)
PT (1) PT3045474T (enExample)
SG (2) SG10202010568RA (enExample)
SI (1) SI3045474T1 (enExample)
SM (1) SMT202100153T1 (enExample)
WO (1) WO2010115868A2 (enExample)
ZA (1) ZA201107215B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790675C (en) * 2005-07-19 2016-12-20 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
WO2015136557A2 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
JP6842926B2 (ja) * 2014-06-30 2021-03-17 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５ベース分子及びその使用方法
EP3191129A4 (en) * 2014-09-10 2018-03-14 The Regents of The University of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
SI3555132T1 (sl) * 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
SG11202011170YA (en) * 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof
WO2019243898A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods for improving response to anti-lif antibody treatment in individuals with cancer
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
EP3957324A4 (en) * 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP3046318B2 (ja) 1987-12-15 2000-05-29 ジーン・シアーズ・ピーティーワイ・リミテッド リボザイム
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
KR100704140B1 (ko) * 1999-02-12 2007-04-09 더 스크립스 리서치 인스티튜트 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2004016758A2 (en) * 2002-08-15 2004-02-26 Genzyme Corporation Brain endothelial cell expression patterns
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
KR20070085113A (ko) * 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
BRPI0912927A2 (pt) * 2008-08-29 2019-10-01 Genentech Inc "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof

Also Published As

Publication number Publication date
LT3045474T (lt) 2021-05-10
EP2414394A2 (en) 2012-02-08
SI3045474T1 (sl) 2021-07-30
KR20220035978A (ko) 2022-03-22
ES2363358A1 (es) 2011-08-01
JP2022031742A (ja) 2022-02-22
KR20170121319A (ko) 2017-11-01
SG175032A1 (en) 2011-11-28
AU2010233791B2 (en) 2016-01-21
HUE054196T2 (hu) 2021-08-30
CA2757680C (en) 2021-11-02
CN107964043A (zh) 2018-04-27
DK3045474T3 (da) 2021-03-22
KR20200078668A (ko) 2020-07-01
ZA201107215B (en) 2012-12-27
JP6207836B2 (ja) 2017-10-04
EP3045474A3 (en) 2016-09-28
BRPI1015369A2 (pt) 2021-06-29
JP2012522756A (ja) 2012-09-27
SG10202010568RA (en) 2020-11-27
CN102574918A (zh) 2012-07-11
HRP20210352T1 (hr) 2021-05-28
US20200385455A1 (en) 2020-12-10
EP3045474B1 (en) 2021-01-13
CA2757680A1 (en) 2010-10-14
US10100112B2 (en) 2018-10-16
EP3045474A2 (en) 2016-07-20
US20120114671A1 (en) 2012-05-10
KR20180079470A (ko) 2018-07-10
AU2010233791A1 (en) 2011-11-03
ES2864639T3 (es) 2021-10-14
JP2016040255A (ja) 2016-03-24
JP2020090522A (ja) 2020-06-11
KR102373754B1 (ko) 2022-03-15
JP7197665B2 (ja) 2022-12-27
KR20120100703A (ko) 2012-09-12
US20240400667A1 (en) 2024-12-05
IL215467A0 (en) 2011-12-29
MX2011010425A (es) 2012-03-06
IL215467A (en) 2016-06-30
JP2019006784A (ja) 2019-01-17
SMT202100153T1 (it) 2021-05-07
MX336903B (es) 2016-02-04
PL3045474T3 (pl) 2021-08-09
WO2010115868A2 (en) 2010-10-14
US11999782B2 (en) 2024-06-04
KR20190093691A (ko) 2019-08-09
US20190211095A1 (en) 2019-07-11
CY1124148T1 (el) 2022-05-27
PT3045474T (pt) 2021-03-22
EA201101450A1 (ru) 2012-04-30
WO2010115868A3 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
ES2363358B1 (es) Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif
KR20250036314A (ko) Pdk3 저해제를 포함하는 말초신경종양 예방 또는 치료용 약학 조성물 및 이의 용도
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
KR20250036293A (ko) Ilk 저해제를 포함하는 말초신경종양 예방 또는 치료용 약학 조성물 및 이의 용도
KR20240153453A (ko) IGFBP5 발현 억제용 shRNA를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: FUNDACIO PRIVADA INSTITUT DINVESTIGACIO ONCOLOGIC

Effective date: 20111102

FG2A Definitive protection

Ref document number: 2363358

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120621

FA2A Application withdrawn

Effective date: 20121120